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ABSTRACT
Human genetic diseases have been successfully
corrected by integration of functional copies of the
defective genes into human cells, but in some cases
integration of therapeutic vectors has activated
proto-oncogenes and contributed to leukemia. For
this reason, extensive efforts have focused on
analyzing integration site populations from patient
samples, but the most commonly used methods
for recovering newly integrated DNA suffer from
severe recovery biases. Here, we show that a new
method based on phage Mu transposition in vitro
allows convenient and consistent recovery of inte-
gration site sequences in a form that can be
analyzed directly using DNA barcoding and pyro-
sequencing. The method also allows simple estima-
tion of the relative abundance of gene-modified
cells from human gene therapy subjects, which
has previously been lacking but is crucial for detect-
ing expansion of cell clones that may be a prelude to
adverse events.
INTRODUCTION
Human gene therapy has been carried out successfully for
several diseases (1–8), but adverse events have occurred in
which subjects developed leukemia associated with
insertion of therapeutic vectors near proto-oncogenes
(3,6,9,10). For this reason, it is important to track the
location and abundance of different integration sites in
cells from gene therapy-treated subjects. Tracking integra-
tion sites is also of interest in the use of transposons as
insertional mutations in model organisms and in basic
studies of integrating genomic parasites (11,12).
In the previously used protocols for integration site
recovery in gene therapy, gene-corrected cells were
isolated from patients, genomic DNA was puriﬁed and
samples were typically cleaved with restriction enzymes.
The exposed DNA ends were then ligated to adaptor
DNAs and samples ampliﬁed using PCR with one
primer complementary to the adaptor and the other com-
plementary to the vector DNA terminus. Sites of integra-
tion were identiﬁed by sequencing PCR products from a
primer bound to the vector DNA, so that the sequence
read extended into the ﬂanking human DNA (13,14). It
was noticed, however, that integration sites were not
equally recovered by different enzymes, pointing to a
recovery bias for this method. Although sites were efﬁ-
ciently recovered when found near restriction cleavage
sites, they were difﬁcult to detect when not positioned op-
timally (15,16). Moreover, implementing restriction
enzyme-based methods is complex—restriction enzymes
need to be identiﬁed, which do not cleave DNA within
amplicons of interest, only enzymes lacking CpG di-
nucleotides in their recognition sites can be used due to
biased distributions of CpG in mammalian DNA, and
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intense interest in alternative approaches.
Improved methods are starting to be described, but all
are in early stages (15–18). Concerns with available
approaches include efﬁciency of recovery of rare integra-
tion sites (16), and the need for large amounts of genomic
DNA for analysis (17,18), which is often not available in
gene therapy applications.
Here we report a method for recovering sites of inte-
grated DNA using the bacterial transposase MuA to
introduce adaptors into genomic DNA to allow PCR
ampliﬁcation. This method is quick and simple, avoids
the bias associated with restriction enzymes, recovers in-
tegration sites in a near random fashion, and provides a
simple measure of cell clonal abundance.
MATERIALS AND METHODS
Cell lines and gene therapy patient samples
293T and SupT1 cells were infected in vitro using a VSV-G
pseudotyped MLV or HIV vector produced by transfect-
ing 293T cells. To generate HIV-based vectors, cells were
transfected with the LTR–GFP cassette plasmid
p156RRLsin-PPTCMVGFPWPRE (19), the packaging
construct pCMVdeltaR9 (20) and the vesicular stomatitis
virus G-producing plasmid pMD.G. VSV-G pseudotyped
MLV particles were produced using pMD.G but in com-
bination with the MLV vector segment (pMX-eGFP) and
packaging construct pCGP (pCGP, kindly provided by
Paul Bates). Human gene therapy samples consisted of
PBMCs (b-thalassemia) or CD3+ cells (SCID-X1).
Details of gene therapy samples are reported elsewhere
(1,2,7,8). The production of induced pluripotent cells con-
taining a deﬁned number of integration sites is reported in
(21).
Mu-mediated integration site recovery
A detailed protocol for preparing Mu reactions is avail-
able in the Supplementary Report 1 MuSOP. Brieﬂy,
reaction buffer, oligonucleotide donor, target DNA and
water are mixed on ice followed by addition of puriﬁed
Mu transposase. Reactions are then incubated at 30 C for
2–4h after which 2ml of the reaction is used as input for
PCR. Nested PCR was carried out as described (22) except
that extension temperatures during cycling were changed
to 70 C for the ﬁrst seven cycles followed by 67 C for the
remaining 37 cycles for samples with HIV-derived vectors.
For both HIV- and MLV-based reactions, the number of
cycles was reduced to 25 for nested PCR. Single round
PCR ampliﬁcation was performed with primers normally
used in the nested round of PCR, each primer encoding
454 adaptor sequences and the LTR primer encoding a
DNA barcode (15).
Integration site sequencing and analysis
Integration sites were sequenced using 454 FLX platform
technology. Sequences reads were trimmed to remove pri-
mer sequence and aligned to the human genome (hg18,
version 36.1) using BLAT. Sequences were required to
have a single best hit with  98% identity to the human
genome, to align within 3bp of the beginning of the se-
quence read and to contain a perfect match to the expected
LTR sequence lying downstream of the barcoded LTR
primer. Comparisons to genomic features were carried
out as described previously (23,24) using a combination
of logistic regression and Bayesian model averaging
supplemented by the random Forest machine learning al-
gorithm. Gene expression analyses were based on data
from 293T cells (25) with expression measured using the
Affymetrix HU133 plus 2.0 gene chip array. Measuring
sequence conservation at the site of restriction enzyme
or Mu cleavage was performed using weblogo [http://
weblogo.berkeley.edu/ and (26)]. Statistical details for
generating Lorentz curves and recovery probability plots
can be found in Supplementary Report 2 Mu Recovery.
Sequence data from this study was submitted to Genbank
under accession numbers HR819863–HR863973.
RESULTS
We ﬁrst quantiﬁed biases in the detection of integrated
DNA using protocols relying on restriction enzyme cleav-
age of genomic DNA. Analysis of the recoverability of an
integration site based on its proximity to the nearest re-
striction site showed that integrated DNA  49bp from
a cleavage site was recovered most frequently, and fre-
quency of recovery decreased sharply at longer or
shorter distances (Figure 1A). The case of SCID-X1
patient 10 provides an example of complications due to
this recovery bias (3,7). In this patient, an integrated
vector activated expression of the nearby BMI1
proto-oncogene, which was associated with massive ex-
pansion of leukemic cells. When DNA from blood cells
of patient 10 was cleaved and analyzed using four different
restriction enzymes, only two enzymes allowed efﬁcient
recovery of the BMI1 integration site (Figure 1B). In an
extreme effort to circumvent these limitations, a study of
SCID-X1 gene-corrected patients used up to six different
restriction enzymes to analyze each individual sample, but
even with the difﬁculty and expense of this large scale
effort, recovery was still signiﬁcantly biased (7).
The improved method reported here (Figure 1C and D)
substitutes MuA-directed transposition in vitro for restric-
tion enzyme cleavage and adaptor ligation [for background
and reviews of MuA function see (11,27–33)]. An engineered
transposon end is used as donor (Figure 1C), which
contains (i) binding sites for the MuA transposase;
(ii) an adaptor region complementary to PCR primers;
and (iii) an amine blocking group at one DNA 30-end.
In the presence of MuA transposase, the oligonucleotide
donors become covalently joined to target DNA, allowing
convenient installation of primer sites in human genomic
DNA. PCR ampliﬁcation is then carried out using primers
complementary to the vector DNA end and the adaptor.
Because the adaptor contains a 50 overhang and an amino-
modiﬁed 30-end, ampliﬁcation must begin within the
vector DNA and extend through the adaptor, preventing
adaptor-to-adaptor ampliﬁcation. As little as 100ng of
genomic target DNA can be used.
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enzyme method, and can be used with the Mu-mediated
method. However, tests showed that for samples contain-
ing relatively large numbers of integrated vectors, only a
single round of PCR was sufﬁcient to yield high quality
sequence populations using the Mu-mediated method, and
these data sets actually showed improved diversity
(described in Supplementary Report 1 ‘Mu Standard
Operating Procedure’).
The PCR primers used for the ﬁnal ampliﬁcation step
are composites, containing both the priming sequences
and sequences required for 454/Roche pyrosequencing.
Primer sequences also contain a DNA barcode between
the 454 sequence and the priming region, allowing large
numbers of amplicons to be pooled, sequences deter-
mined, then sequence reads parsed using the barcodes
(Figure 1D) (34–36). Thus, hundreds of samples can be
processed in pools. Pyrosequence reads are then trimmed,
aligned to the human genome and distributions analyzed.
To test the Mu-mediated method, we determined 25194
total integration site sequences, which yielded 3382 unique
vector integration sites after condensing duplicates. We
analyzed both HIV- and g-retrovirus-based vectors.
Samples studied included cells from patients in two gene
therapy trials, which treated SCID-X1 (3) and
b-thalassemia (8) and tissue culture cells infected in vitro
(summarized in Supplementary Table S1).
We ﬁrst compared recovery biases of the Mu and re-
striction enzyme-based methods. We determined the
sequence preferences for Mu integration in human DNA
in vitro for 5968 integration site sequence reads that
included the Mu-end oligonucleotide DNA. Alignment
of human sequences at Mu integration sites revealed a
detectable consensus sequence closely resembling that
reported previously for Mu transposition (37), but with
much lower information content than cleavage sites for re-
striction enzymes (Figure 2A and B and Supplementary
Report 2), indicating less bias in the cleaving/joining
reactions.
The performance of the restriction enzyme method was
next compared with the Mu-mediated method by measur-
ing recovery biases for each method, then annotating the
human genome for calculated recovery rates based on the
data. Thus, for any integration site in the human genome,
A
B
C
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Figure 1. The Mu-based integration site recovery method. (A) Severe recovery biases in previous methods using restriction enzyme cleavage. A large
collection of integration sites generated from SCID-X1 gene therapy (Supplementary Table S1) were analyzed and plotted to show the relative
recovery frequency for different distances between the restriction enzyme site used in genomic DNA cleavage and the vector integration site. The
graph summarizes data obtained using six different restriction enzymes. The sharp peak documents the recovery bias (the location of the peak
differed modestly for the different restriction enzymes studied; data not shown). (B) Biased recovery efﬁciency for four restriction enzymes in a
sample from an adverse event. The integration site within BMI1 was implicated in an adverse event in SCID-X1 patient 10 (3). Each bar indicates the
percent of all integration sites from the leukemic cell sample deriving from the BMI1 site for each of the three restriction enzymes or three 6-cutter
cocktail (Avr I, Spe I and Nhe I) used for isolation. (C) The engineered Mu DNA donor used in these studies. 50 and 30 DNA ends are as marked.
The ‘N’ indicates the position of an amino-modiﬁer that blocks the DNA 30-end to prevent adaptor-to-adaptor ampliﬁcation. The dark blue indicates
binding sites for MuA transposase, light blue a spacer region and green the adaptor sequence for PCR ampliﬁcation. (D) The Mu-mediated
integration site recovery method. MuA transposition is used to install the engineered Mu DNA donor (top), allowing PCR ampliﬁcation
(middle). The PCR primers contain DNA barcodes (black segments) and primers for use in 454/Roche pyrosequencing (orange). PCR products
can be used directly for pyrosequencing without cloning in bacterial plasmids.
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calculated for each recovery method (Supplementary
Report 2).
Figure 3A illustrates the relative recovery frequencies
using the LMO2 promoter as an example, which was
chosen because the gene has been involved in several
adverse events in SCID-X1 gene therapy (3,38). Note
that although Figure 3A summarizes results on a single
region of the genome, the biases were measured genome-
wide from integration site data for each method and are
shown at LMO2 for purposes of illustration. Recovery
was relatively consistent for the Mu-mediated method
over all sites, whereas the restriction enzyme methods
show sharp peaks and valleys, where valleys indicate lo-
cations where an integration event would be difﬁcult or
impossible to isolate and the peaks frequently recovered
sites that would mask more rare sites. Figure 3B shows the
data plotted as the cumulative recovery frequency, where
perfectly unbiased recovery would be indicated by a curve
that followed the diagonal from lower left to upper right.
The Mu-mediated recovery method most closely ap-
proaches the diagonal and is signiﬁcantly closer than even
the method using six restriction enzymes (P<0.001; see
Supplementary Report 2 for statistical methods), docu-
menting that the Mu-mediated method is the least biased.
Another means of quantifying recovery biases involves
comparing the increased sampling effort required to reach
the results of a perfectly unbiased method. The slight
biases introduced by the Mu method would require only
a 10% increase in sampling effort to achieve the efﬁciency
of a perfectly unbiased method (Supplementary Report 2).
In contrast, for some restriction enzyme methods, the
needed increase is too large to measure accurately
(>50-fold). For the pool of all six restriction enzymes, a
45% increase in effort would be needed. Thus the Mu-
mediated method yields less biased recovery with much
less effort than any form of restriction enzyme-based
method.
We next investigated the experimental effort required to
recover all members of a fully deﬁned integration site
population using the Mu-based method. We prepared an
induced pluripotent stem (iPS) cell line in which all cells
contained the same six known lentiviral vector integration
sites. We carried out 12 independent integration site recov-
ery reactions using the Mu-mediated method, recovering
an average of 1068 sequence reads per replicate. We found
that six of the 12 replicate reactions recovered all six sites.
The replicates with fewer than six yielded either four or
ﬁve of the sites. To assess the sampling effort required for
recovery of all six sites, we pooled different numbers of
Mu reactions computationally and assessed recovery. For
pools of three of the 12 Mu reactions, 98% contained all
six sites. For pools of ﬁve Mu reactions, 100% of the pools
contained all six sites. Thus, 3–5 independent Mu reac-
tions are enough to completely sample an integration
site population of this size at the sequencing depth used.
For comparison, three restriction enzymes were tested for
recovery of the six sites, and only one yielded all six.
The genome-wide distribution patterns of integration
target sites for HIV and g-retroviruses have been studied
extensively (13,14,23,39,40), allowing us to assess whether
the Mu-mediated method reported similar trends. For
studies of integration frequency near genomic landmarks,
restriction enzyme-based methods usually provided an
adequate overview, because the restriction biases are
only weakly related to those landmarks. Figure 4A and
B compares the distributions of integration sites isolated
using the two methods for HIV and g-retrovirus-based
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Figure 2. Consensus sequences at points of adaptor addition.
(A) Information content at junctions between the engineered Mu
DNA and human DNA derived from vector integration site sequence
reads. The x-axis shows the DNA sequence position, where the site of
joining to Mu DNA is between positions 10 and 11 (arrow). Perfect
sequence conservation has information content of 2 bits (y-axis). Note
that some bases have little or no information content, so no letters are
visible. (B) Information content at adaptor junctions from vector inte-
gration sites recovered after cleavage with the restriction enzyme Mse I,
where the site of cleavage is between positions 10 and 11 (arrow).
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tissue culture cells and for one SCID-X1 patient (3,7).
Figure 4A summarizes the relationship of integration
sites to genomic features, using a heat map format to
indicate increased or decreased integration frequency
compared with random distributions. For both HIV and
g-retroviral vectors, the genome-wide trends were closely
similar for the Mu-mediated or restriction
enzyme-mediated methods. Both HIV-based and
g-retrovirus-based vectors favor integration in regions of
high gene density and associated genomic landmarks.
Gamma-retroviruses favor integration near gene 50-ends.
HIV and g-retroviruses show a complex pattern of favored
and disfavored integration sites near regions of histone
methylation, acetylation and bound proteins, as indicated
by comparison to data from ChIP-seq experiments (41–
44) (Figure 4B), again showing favored integration near
marks of active transcription. These patterns matched
closely for the Mu-mediated and restriction-enzyme-
based methods. The genome-wide patterns for SCID-X1
gene therapy closely paralleled those seen for g-retroviral
vectors, as reported previously (3,6,7). Thus, conclusions
on genome-wide distributions of integration sites from the
Mu-mediated method parallel those from extensive
previous studies.
The Mu-mediated method also allows a new approach
to quantifying the relative frequency of gene-corrected
cells in patient samples. Gene corrected cell clones that
are present in many copies will contribute a relatively
larger proportion of their integration site DNA to the
genomic DNA pool after puriﬁcation, providing an incr-
eased number of target sites for Mu integration in vitro.A s
a result, relatively larger numbers of independent Mu
integration events will lead to recovery of the same high
abundance vector integration site. Quantifying the number
of independent Mu integration sites per vector integration
site therefore provides a simple measure of the relative
abundance.
We tested this in a sample from a b-thalassemia gene
therapy trial, in which a cell harbouring a single vector
integration site in the HMGA2 gene expanded to comprise
more than one-third of the gene-corrected peripheral
blood mononuclear cells (PBMC) population, as docu-
mented by quantitative PCR assays (8). We recovered 10
independent Mu integration sites for the HMGA2 vector
integration site, while all other vector integration sites
were recovered with only a single Mu site (Figure 4C).
This ﬁnding makes the important clinical point that the
HMGA2 site is the only high abundance integration site in
the expanded cell clone. Using the restriction enzyme
cleavage method for integration site recovery, only two
out of three of the enzymes used allowed isolation of the
HMGA2 site (data not shown).
Lastly, we present a method for suppressing PCR con-
tamination. In assessing collections of gene therapy sam-
ples, multiple tubes are commonly processed in parallel
using nested PCR, providing an ideal setting for migration
of PCR products between samples. In practice controlling
B A
Figure 3. Reduced recovery bias using the Mu-mediated integration site isolation method. (A) Relative recovery rates compared at the LMO2
promoter for (i) the Mu-mediated method; (ii) six tests with single restrictions enzymes or pools or (iii) a mixture of all six. The recovery rates were
calculated from data on the placement of integration sites relative to restriction enzyme cleavage sites or Mu transposase sites used in their isolation,
using the data in Supplementary Table S1 and statistical methods described in Supplementary Report 2. Calculated integration site recovery rates
were then used to annotate each base over 10kb at the LMO2 promoter (chr11, bases 33770412–33780411). ‘Six enzymes’ indicates pooled data for
the six sets below. For a perfectly unbiased method, all such rates equal 1.0. (B) Statistical analysis of biases in recovery of integration sites. The
x-axis plots each base of the LMO2 promoter analyzed above, treating each as a potential integration target. Sites were ranked by expected ease of
isolation, with the easiest to isolate to the right. The y-axis shows the calculated proportion of sequences recovered given the measured recovery
biases. Perfect unbiased recovery would follow a line from lower left to upper right. Statistical methods and P values for pair-wise comparisons are
summarized in Supplementary Report 2.
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mentalists. We have devised a method that suppresses this,
in which separate adaptors are used for each sample, so
that contaminating PCR products are not ampliﬁable
outside the correct PCR reaction. In reconstruction ex-
periments, this has been effective at suppressing cross-over
in our laboratory (data not shown). Use of multiple
adaptors is described in the Standard Operating
Procedure in the Supplementary Data for this article.
DISCUSSION
In summary, the Mu-mediated integration site recovery
method allows simpliﬁed recovery of integration sites
and estimation of relative abundance. Use of protocols
based on single restriction enzymes results in failure to
isolate integration sites that are not near restriction
enzyme recognition sites (7,15,16), which can be crucial
in monitoring adverse events during gene therapy. The
challenges posed by biased isolation have been under-
estimated in some of the early literature in this ﬁeld.
One previous study attempted to circumvent recovery
biases by using six restriction enzymes to study single
samples, but even with this added complication and
expense, recovery using this method is still more biased
than with the Mu-based method (Figure 3B; P<0.001).
Thus in cases where it is critical to use integration site
data to identify expanded cell clones, the Mu method is
attractive and convenient.
Methods for deep sequencing are in a state of rapid tran-
sition. The Mu-mediated method described here can in
principal be adapted to any of the next generation se-
quencing platforms. At this writing, the Solexa/Illumina
method is least expensive per base, but potentially incon-
venient because analysis of a handful of samples will often
take up only a fraction of a run, requiring complicated
A
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Figure 4. Mu-mediated integration site recovery. (A) Integration frequency near genomic land marks. (B) Integration frequency near sites of histone
methylation, acetylation or bound chromosomal proteins. Data sets compared are indicated by the column headings, features analyzed by the rows.
Heat maps were constructed using the receiver operating characteristic (ROC) area method to compare the observed distributions to random
distributions of integration sites (23,45). ROC areas of 0.5 indicated integration sites are present near the indicated genomic features as often as
expected by chance. ROC areas >0.5 indicate positive association and areas <0.5 negative association. Associations are colour coded as indicated by
the key at the bottom of each map. In (A), for the Gene Density, Expression Density and GC content measures, several different length genomic
intervals were used for comparisons, which are indicated by numbers to the right of the black bar. In (B), ChIP-seq analysis was used to map the
genome-wide distributions of sites of histone post-translational methylation or acetylation, or bound DNA binding proteins (41–44), and the results
compared with integration site distributions. Statistical analysis shows that most associations where discernable colour can be seen in a heat-map tile
achieve statistical signiﬁcance. (C) Comparisons of the numbers and positions of Mu integration sites that allowed recovery of the vector integration
sites at HMGA2, VPS13B and POLA2 generated during gene therapy for b-thalassemia.
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method is more expensive per base, but the availability of
a benchtop instrument for smaller runs (the ‘Junior’ in-
strument http://www.gsjunior.com/) simpliﬁes through-
put. It is highly likely that additional sequencing
methods will become available in the near future that
may also be useable with the Mu-mediated method.
The demands placed on integration site recovery tech-
nology vary by disease state. The frequency of gene cor-
rected cells varies from 100% (T cells in SCID-X1) to
<1% [early adenosine deaminase (ADA) studies], so the
demands on the technology differ for different diseases.
For very low level clones, recovering integration sites
and estimating their abundance is at present challenging
for any technology.
Additional methods are starting to be proposed for in-
tegration site analysis, including methods based on DNA
shearing (N. Gillet, N. Malani, N. Gormley, R. Carter, A.
Melamed, D. Bentley, C. Berry, F. Bushman, G. Taylor
and C. Bangham, submitted for publication) or limited
extension from integrated vectors with a DNA polymerase
followed by RNA ligation (‘nrPCR’) (16). Each of these
methods is of interest but each may have inefﬁcient steps.
For the Mu-mediated method, it can be challenging to
obtain enough Mu integration events to query the full
human genome efﬁciently, though the method is suitable
for analysis of large numbers of samples with small
amounts of starting genomic DNA. Ongoing use has
shown the method to be effective in practice. For DNA
shearing, it can be challenging to obtain efﬁcient ligation
after repairing broken DNA ends, and to work with small
amounts of DNA. For the nrPCR method, efﬁciency may
be an issue (16).
Two reports in the peer-reviewed literature document
the utility of the Mu-mediated method. In one case,
oligoclonal reconstitution during lentiviral vector-
mediated gene correction was documented using
Mu-mediated recovery of integration sites during
b-thalassemia gene correction in mice (46). In this case,
the inferred rank order of integration site abundance from
sequence read counts was similar to that inferred by quan-
tifying the number of independent Mu-transposition
events in vitro that led to site recovery. The congruence
of these two measures supports the idea that quantiﬁca-
tion relative to clonal abundance was consistent. In the
second study (21) the Mu-mediated method was used
along with other methods and found to be comparably
efﬁcient. Long term, it will be useful to compare the ef-
fectiveness and convenience of present and future methods
for quantifying integration site abundance on deﬁned in-
tegration site populations.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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